Proteomics

Dataset Information

0

Proteomic analysis of paclitaxel-tolerant ovarian cancer OVCAR8-Persister cells revealed a metabolic shift to fatty acid oxidation


ABSTRACT: Human ovarian adenocarcinoma OVCAR8 cells and paclitaxel-induced OVCAR8 -Persister cells (3 biological replicates) were collected in lysis buffer and then sonicated three times on ice. The supernatant represented the whole-cell extract. 4D-data independent acquisition (DIA)-based label-free quantitative proteomics was performed on a timsTOF Pro2 (Bruker Daltonics, USA) mass spectrometer coupled to a nanoElute UHPLC system (Bruker Daltonics, USA).

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Malignant Cell

DISEASE(S): Malignant Neoplasm Of Ovary

SUBMITTER: Hui Lin  

LAB HEAD: Weiguo Lu

PROVIDER: PXD048089 | Pride | 2026-01-12

REPOSITORIES: Pride

Dataset's files

Source:
altmetric image

Publications

Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells.

Lin Hui H   Wang Lingfang L   Chen Hanwen H   Shen Yuqing Y   Wang Conghui C   Xue Yite Y   Zheng Zhi Z   Zhang Yanan Y   Xia Dajing D   Wu Yihua Y   Wang Fenfen F   Li Xiao X   Cheng Xiaodong X   Wang Hui H   Xu Junfen J   Lu Weiguo W  

Journal of advanced research 20250317


<h4>Introduction</h4>Cancer patients treated with current chemotherapeutic and targeted therapies frequently achieve partial remission, which ultimately relapse with more aggressive, drug-resistant tumor phenotypes. To a certain extent, drug-tolerant persister (DTP) cells are responsible for residual tumors after systemic anticancer therapy and the onset of acquired drug resistance. Therefore, novel therapies targeting DTP cells to prevent drug resistance and tumor recurrence are urgently needed  ...[more]

Similar Datasets

2025-08-16 | PXD066948 | Pride
2024-06-07 | PXD045439 | Pride
2018-11-02 | PXD009808 | Pride
2019-12-11 | PXD014310 | Pride
2025-07-30 | PXD057016 | Pride
2018-04-05 | PXD005350 | Pride
2024-01-26 | PXD045069 | Pride
2013-07-22 | PXD000126 | Pride
2024-04-30 | PXD048597 | Pride
2023-05-10 | PXD029085 | Pride